Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Nonvalvular AF (NVAF) verified by at least two ECGs in the last year separated by at least one week.~* Previous cerebral ischemic attack (stroke or TIA, \>30 days prior to randomization)~* Previous systemic embolism.~* Symptomatic congestive heart failure (CHF)~* Impaired left ventricular systolic function~* Diabetes mellitus~* Hypertension requiring anti-hypertensive treatment.~Exclusion Criteria:~* AF secondary to reversible disorders, eg hyperthyroidism, drugs and pulmonary embolism~* Known contraindication to VKA treatment~* Presence of a valvular heart disease, mechanical heart valves, active endocarditis, left ventricular aneurysm or thrombus, atrial myxoma or any condition other than AF requiring chronic anticoagulation treatment~* Conditions associated with increased risk of major bleeding for example: history of intracranial bleeding, history of bleeding gastrointestinal disorder or major surgical procedure or trauma two weeks prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD0837 450 mg
- 2 (Type: EXPERIMENTAL): AZD0837 200 mg
- 3 (Type: EXPERIMENTAL): AZD0837 300 mg
- 4 (Type: EXPERIMENTAL): AZD0837 150 mg
- 5 (Type: ACTIVE_COMPARATOR): Vitamin-K antagonist at INR 2-3

Based on this trial design, predict the completion outcome and termination type (if applicable).